Table I.
Patient and treatment characteristics
| ∗ | BPO (n = 93) |
Azelaic acid (n = 246) | Adapalene (n = 254) | A/BPO (n = 264) | Clin-RA (n = 303) | All therapies confounded (n = 1160) |
|---|---|---|---|---|---|---|
| Patient characteristics | ||||||
| Male, n (%) | 49 (53) | 44 (18) | 110 (43) | 85 (32) | 133 (44) | 371 (36) |
| Mean age at treatment, years (SEM) | 25.1 (0.9) | 22.6 (0.6) | 21.8 (0.5) | 22.6 (0.4) | 22.4 (0.5) | 22.8 (0.3) |
| Mean duration of acne, months (SEM) | 71.3 (7.8) | 53.0 (5.0) | 57.4 (4.6) | 70.0 (4.5) | 58.0 (4.0) | 60.9 (2.4) |
| Treatment status at the moment of data lock†,‡ | ||||||
| Active, n (%) | 3 (3) | 27 (11) | 9 (4) | 11 (4) | 35 (12) | 85 (7) |
| Discontinued, n (%) | 90 (97) | 219 (89) | 245 (96) | 253 (96) | 268 (88) | 1075 (93) |
| Drug duration | ||||||
| Median calculated drug duration, m | 3 | 2 | 2 | 2 | 2 | 2 |
| Controlled acne, n (%) | 1 (1) | 30 (12) | 24 (9) | 12 (5) | 41 (14) | 108 (9) |
| Side effects, n (%) | 14 (15) | 8 (3) | 21 (8) | 27 (10) | 20 (7) | 90 (9) |
| Ineffectiveness, n (%) | 55 (60) | 111 (45) | 137 (54) | 142 (54) | 100 (33) | 545 (52) |
| Side effects plus ineffectiveness, n (%) | 4 (4) | 4 (2) | 5 (2) | 13 (5) | 5 (2) | 32 (3) |
| Other (non-compliance, pregnancy, cost), n (%) | 0 (0) | 2 (1) | 4 (2) | 3 (1) | 6 (2) | 15 (1) |
| Lost to follow-up, n (%) | 21 (23) | 69 (28) | 62 (24) | 61 (23) | 105 (35) | 318 (27) |
BPO, Benzoyl peroxide; A/BPO, fixed combination of adapalene 0.1% and BPO 2.5%; Clin-RA, fixed combination of clindamycin 1.2% and tretinoin 0.025% gel; SEM, standard error of the mean.
∗
Values are given as n (%) unless otherwise indicated.
†
Data lock occurred in December 2019.
‡
Patients can be successively treated with different drugs. A single patient can be categorized by side effects and also by the lack of efficacy of the same drug.